The FAR NHL register and humoral activation

Česká verzia

Authors: Špinarová L. ¹; Špinar J. ¹; Pařenica J. ²; Ludka O. ¹; Málek F. ³; Lábr K. ¹; Špinarová M. ¹; Krejčí J. ¹; Jarkovský J. ⁴; Goldbergová-Pávková M. ⁵; Tomandl J. ⁶
Authors place of work: I. interní kardioangiologická klinika LF MU a FN u sv. Anny v Brně ¹; Interní kardiologická klinika LF MU a FN Brno ²; kardiologické oddělení, Nemocnice Na Homolce, Praha ³; Institut biostatistiky a analýz, LF a PřF MU, Brno ⁴; Ústav patofyziologie, LF MU, Brno ⁵; Ústav lékařské chemie a biochemie, LF MU, Brno ⁶
Published in the journal: Kardiol Rev Int Med 2020, 22(2): 51-57

Summary

Chronic heart failure is a clinical syndrome with the activation of various pathophysiological mechanisms. Some of them are vasoconstrictive: sympathetic system, renin angiotensin system, aldosterone, vasopressin and endothelin. Counterbalancing vasodilating agents are: natriuretic peptides, endothelium-dependent relaxation factor and adrenomedullin. The elevation of cytokines or markers of oxidative stress also plays a role. The FAR NHL (FARmacology and NeuroHumoraL activation) register is a database of patients with chronic heart failure (CHF) and is focused on pharmacology and humoral activation. A total of 1,100 patients have been included, the most frequent aetiology of CHF was ischaemic heart disease 49.7%. Routine biochemistry and NT-proBNP was evaluated in all patients. Novel humoral substances and markers of oxidative stress: copeptin, MR-proadrenomedullin (MR-proADM), pentraxin (PTX3), galectin3, soluble lectin-like oxidised LDL receptor-1 (sLOX-1) and 3-Nitrotyrosin (3-NT) were measured in a part of the study population. The primary endpoint after a 1-year follow-up was: death or hospitalisation for decompensation of HF or heart transplantation (HTX) or LVAD implantation. More than 50% of the patients with stable CHF showed a level of NT-proBNP higher than 600 pg/ml. The level of NT-proBNP increased with the NYHA class. Patients without a primary endpoint (death or hospitalisation for decompensation of HF or heart transplantation or LVAD implantation) were assigned as group A, those with a primary endpoint as group B. There were statistically significant differences between the groups in the levels of copeptin, MR-proADM and PTX3 (p < 0.001 for all substances). There were no differences in the levels of other substances: galectin3, NGAL, sLOX-1 and 3-NT. When evaluating comorbidities using the AHEAD score, patients with a higher AHEAD score (more comorbidities) achieved the primary endpoint more often. For both humoral agents: copeptin and MR-proADM, there was a statistically significant importance for achieving the primary endpoint in patients with lower AHEAD scores (p < 0.006 and p < 0.003), however, neither agent showed a significant predictive value in patients with higher AHEAD scores. Higher levels of the new humoral agents (copeptin and MR-proADM) could differentiate CHF patients at a higher risk of adverse events. The predictive value of these agents is also affected by the patient's comorbidities as assessed by the AHEAD score. New humoral agents could thus have an additional value for the already traditional and routinely used natriuretic peptides.

Keywords:

Prognosis – chronic heart failure – humoral activation – FAR NHL registry – AHEAD score

Zdroje

1. Coats JA, Jankowska E, Laincsak M et al. Innovative pharmacological targets and approaches in heart failure. London: Barcaray Int Publishing 2019.

2. Keller T, Tzikas S, Zeller T et al. Copeptin improves early diagnosis of acute myocardial infarction. J Am Coll Cardiol 2010; 55(19): 2096–2106.

3. Petrie MC, McClure SJ, Love MP et al. Novel neuropeptide in the pathophysiology of heart failure: adrenomedullin and endothelin-1. Eur J Heart Fail 1999; 1(1): 25–29. doi: 10.1016/ S1388-9842(98)00013-0.

4. Pousset F, Isnard R, Lechat P et al. Prognostic value of plasma endothelin-1 in patients with chronic heart failure. Eur Heart J 1997; 18(2): 254–258. doi: 10.1093/ oxfordjournals.eurheartj.a015228.

5. Ponikowski PA, Voors A, Anker SD et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Eur Heart J 2016; 37(27): 2129–2200. doi: 10.1093/ eurheartj/ ehw128.

6. Špinar J, Hradec J, Špinarová L et al. Souhrn doporučených postupů ESC pro diagnózu a léčbu akutního a chronického srdečního selhání z roku 2016. Připraven Českou kardiologickou společností. Cor Vasa 2016; 58(5): e530–e560. doi: 10.1016/ j.crvasa.2016.09.004.

7. Pousset F, Mason F, Chavirovskaia O et al. Plasma adrenomedullin, a new independent predictor of prognosis in patiens with chronic heart failure. Eur Heart J 2000; 21(12): 1009–1014. doi: 10.1053/ euhj.1999.1904.

8. Feldman AM, Combes A, Wagner D et al. The role of tumor necrosis factor in the pathophysiology of heart failure. J Am Coll Cardiol 2000; 35(3): 537–544. doi: 10.1016/ s0735-1097(99)00600-2.

9. Takaya T, Wada H, Morimoto T et al. Left ventricular expression of lectin-like oxidized low-density lipoprotein receptor-1 in failing rat hearts. Circ J 2010; 74(4): 723–729. doi: 10.1253/ circj.cj-09-0488.

10. Zhang YL, Wei JR. 3-nitrotyrosine, a biomarker for cardiomyocyte apoptosis induced by diabetic cardiomyopathy in a rat model. Mol Med Reports 2013; 8(4): 989–994. doi: 10.3892/ mmr.2013.1644.

11. Špinar J, Špinarová L, Málek F et al. Prognostic value of NT-proBNP added to clinical parameters to predict two-year prognosis of chronic heart failure patients with mid-ranged and reduced ejection fraction- A report from FAR-NHL prospective registry. Plos One 2019; 14(3): e0214363. doi: 10.1371/ journal.pone.0214363.

12. Špinarová L, Špinarová M, Goldbergová-Pávková M et al. Prognostic impact of copeptin and mid-regional pro-adrenomedullin in chronic heart failure with regard to comorbidities. Cardiovasc Dis Diagn 2018; 6(4): 326. doi: 10.4172/ 2329-9517.1000326.

13. Spinar J, Jarkovský J, Spinarová L et al. The AHEAD investigators. AHEAD score – long-term risk classification in acute heart failure. Int J Cardiol 2016; 202: 21–26. doi: 10.1016/ j.ijcard.2015.08.187.

14. Špinar J, Ludka O, Sepši M. The AHEAD investigators. Atrial fibrillation as prognostic factor of myocardial infarction and/ or acute heart failure. Interventional Medicine and Applied Science 2011; 3(3): 104–107.

15. Anand IS. Anemia and chronic heart failure implications and treatment options. J Am Coll Cardiol 2008; 52(7): 501–511. doi: 10.1016/ j.jacc.2008.04.044.

16. Consuegra-Sánchez L, Núñez J, Fácila L et al. Prognostic impact of anaemia in acute heart failure. Rev Invest Clin 2006; 58(4): 279–284.

17. Lazzarini V, Mentz RJ, Fiuzat M et al. Heart failure in elderly patients: distinctive features and unresolved issues. Eur J Heart Fail 2013; 15(7): 717–723. doi: 10.1093/ eurjhf/ hft028.

18. Kannel WB, Hjortland M, Castelli WP. Role of diabetes in congestive heart failure: the Framingham study. Am J Cardiol 1974; 34(1): 29–34. doi: 10.1016/ 0002-9149(74)90089-7.

19. Parissis JT, Rafouli-Stergiou P, Mebazaa A et al. Acute heart failure in patients with diabetes mellitus: clinical characteristics and predictors of in-hospital mortality. Int J Cardiol 2012; 157(1): 108–113. doi: 10.1016/ j.ijcard.2011.11.098.